BioZorb Lawsuit: An Overview of Legal Claims and Potential Settlements

This page provides a comprehensive overview of the BioZorb lawsuit, exploring the legal and financial ramifications for individuals who have suffered harm due to this medical device. The FDA’s classification of Hologic’s notification to healthcare providers as a Class I recall underscores the serious risk of injury or death associated with the device. This recall brought to light numerous complications, including device migration, infection, and other adverse reactions.

The BioZorb implant, intended as a tissue marker following lumpectomies in breast cancer patients, has been linked to significant complications, such as chronic pain, scarring, and the necessity for additional surgeries. Despite its intended purpose of aiding recovery, the device has resulted in outcomes that were not fully disclosed by its manufacturer, Hologic.

Our attorneys at Nguyen Injury Lawyer will examine the background of BioZorb’s titanium breast markers, the legal allegations surrounding its use, and provide early insights into potential BioZorb settlement amounts and jury awards.

If you have experienced complications related to a BioZorb implant device, it is crucial to act swiftly. Contact Nguyen Injury Lawyer today at XXX-XXX-XXXX or through our online contact form. There are no fees unless we secure compensation for your injuries.

🔍 BioZorb Lawsuit at a Glance – June 2025

• Overview
• Defendant: Hologic, Inc.
• Product: BioZorb Marker – post-lumpectomy breast implant
• Issue: Device migration, infection, non-resorption, chronic pain
• Regulatory Action: FDA Class I Recall (highest severity), FDA Warning Letter (Jan 2025)
• Litigation Type: Consolidated cases (non-MDL) in U.S. District Court, Massachusetts
• Judge: Hon. Allison D. Burroughs

⚖️ Legal Claims

• Failure to Warn
• Defective Design
• Negligence
• Off-Label Promotion

📅 Key Dates & Developments

• February 2026: Settlement
• January 2026: First bellwether trial expected
• May 2025: Discovery closed; expert phase moving forward
• August 2025: Summary judgment denied

📈 Allegations

• Device failed to resorb as promised (leaving masses, pain, and complications)
• Patients required revision surgeries
• Device marketed for cosmetic benefits, not approved by FDA
• Hologic delayed adverse event reporting

💰 Settlement Estimates

• Severe injury cases could exceed $1 million
• Potential for punitive damages if gross negligence proven

🚨 FDA Findings

• Design and manufacturing did not meet safety standards
• Lack of adequate absorption testing
• Failure to timely report serious adverse events

📌 Plaintiff Criteria

Nguyen Injury Lawyer is evaluating claims from individuals who received a BioZorb implant after a lumpectomy and subsequently suffered from pain, scarring, infection, or required revision surgery.

📞 Contact for Legal Review

Call Nguyen Injury Lawyer at XXX-XXX-XXXX or contact us online to determine your eligibility for compensation.

2025 BioZorb Lawsuit Update

The BioZorb Marker lawsuits are progressing rapidly.

February 15, 2025: Settlement

A global settlement has been reached to resolve all pending BioZorb breast marker lawsuits, bringing an end to litigation over the recalled implant.

August 15, 2025: Plaintiffs Win Big Motion

Hologic’s motion for summary judgment in the BioZorb multidistrict litigation aimed to dismiss two lead cases before trial by challenging the element of causation.

The company contended that the plaintiffs had not presented sufficient expert testimony on either general or specific causation, which they argued was necessary to avoid summary judgment in a complex medical device case. According to the defense, the plaintiffs’ claims lacked the required legal basis to be presented to a jury without this expert support.

The court rejected this argument, denying the motion and concluding that a triable issue exists regarding causation. This decision means that the plaintiffs’ expert testimony and scientific evidence will be considered at trial. It confirms that the causation issue is adequately supported to allow a jury to determine whether the BioZorb device caused the alleged injuries.

Had the motion been granted, it would have excluded the scientific evidence and resulted in the dismissal of the claims. Instead, the ruling ensures that these cases will proceed to trial, where a jury will evaluate the expert testimony and decide whether the company is liable.

Plaintiffs’ attorneys express strong confidence as they approach these trials.

June 24, 2025: Pushing Cases to Trial

Two BioZorb cases have largely completed fact discovery, which officially closed last month. The expert phase is now underway.

May 3, 2025: 122 BioZorb Lawsuits and Counting

In a joint status report submitted to Judge Allison Burroughs, both parties confirmed that the consolidated BioZorb litigation has reached 122 filed cases. This update highlights consistent progress as the parties move closer to the first bellwether trial, scheduled for September 2025.

As more former patients report complications linked to the BioZorb device, the increasing number of cases may influence Hologic’s settlement strategy prior to trial.

Plaintiffs’ BioZorb attorneys reported that fact discovery is nearly complete for the initial trial pool, with expert depositions scheduled to continue through the May deadline. This timeline keeps the litigation on track and suggests that the court’s early procedural framework, particularly the structured bellwether selection process, is functioning as intended.

February 21, 2025: Trial Date

Judge Allison Burroughs has scheduled the BioZorb trial for September 8, 2025. This trial will help determine the settlement amounts for the titanium breast marker lawsuit, assuming a global settlement is not reached beforehand.

February 13, 2025: No New Discovery

Attorneys for BioZorb victims filed a motion late last month requesting to reopen discovery, seeking new depositions related to the BioZorb recall, which occurred after most of the bellwether trial preparations had been completed. The court rejected this request, stating that interviewing plaintiffs’ physicians about a recall that occurred months or years after the fact had no relevance.

January 29, 2025: FDA Warning Letter

The FDA’s new BioZorb warning letter heightens concerns for patients implanted with this device. It also further bolsters the claims in the growing BioZorb litigation against its manufacturer.

The FDA found that BioZorb’s design and manufacturing processes failed to meet basic safety and quality standards, including a lack of adequate testing to confirm that the device properly resorbs in the body as intended. This aligns with reports in BioZorb lawsuits of patients experiencing severe complications such as chronic pain, infection, tissue damage, and the need for surgical removal of the device years after implantation.

The FDA’s inspection also revealed that Hologic failed to properly account for how the device might interfere with cancer detection or respond to radiation treatments. These are critical considerations for the breast cancer patients for whom BioZorb was heavily marketed. These failures, combined with a surge in reported adverse events in 2023, suggest that the manufacturer was aware of the serious risks associated with BioZorb but failed to take appropriate action.

For plaintiffs, this FDA warning letter strengthens claims that Hologic negligently designed and marketed BioZorb without adequately assessing its long-term safety. The FDA’s conclusion that Hologic’s response was inadequate, even after the company announced it would discontinue BioZorb, adds significant weight to the argument that the device should never have been sold in the first place.

The FDA also cited Hologic for failing to report serious adverse events within the legally required timeframe, raising questions about how long the company concealed evidence of BioZorb’s dangers from doctors and patients.

January 16, 2025: Big Win for Plaintiffs

Judge Burroughs denied Hologic’s motion for summary judgment in a case involving allegations that the company failed to adequately warn a surgeon about risks associated with its BioZorb radiographic marking device.

The plaintiff, a South Carolina resident, alleges that the device caused severe complications requiring multiple surgeries due to inadequate warnings about its performance. She underwent a partial mastectomy in 2020, during which her surgeon implanted the BioZorb device to mark the excision site for radiology. A Hologic representative informed the surgeon that the device’s bioabsorbable material would resorb within six to twelve months, leaving only titanium clips for radiographic imaging. However, complications arose, including pain and an abscess, leading to multiple follow-up procedures to remove parts of the device. The plaintiff’s case is one of 22 consolidated lawsuits, with this case designated as part of the bellwether trial pool.

Hologic argued that the plaintiff failed to demonstrate that stronger warnings would have altered her surgeon’s decision to use BioZorb. The company highlighted deposition testimony suggesting the surgeon could not definitively state whether earlier knowledge of risks, including extended resorption times and adverse event reports, would have changed his treatment plan. However, Judge Burroughs emphasized evidence showing the surgeon’s eventual decision to stop using BioZorb entirely after discovering, through personal experience, that the device did not resorb as quickly as promised. The court concluded that a jury could reasonably infer that earlier warnings might have led the surgeon to avoid using the device in the plaintiff’s case.

In denying summary judgment, Judge Burroughs noted, “A reasonable jury could conclude that a warning from Hologic about [the risk of prolonged resorption] could have caused [the surgeon] not to use the device at all—including in this case.” This ruling allows the plaintiff to present her claims at trial, highlighting potential shortcomings in Hologic’s risk communication and the broader implications for medical device manufacturers.

BioZorb Lawsuit FAQ – What You Need to Know

Is the BioZorb lawsuit the next big breast cancer medical device litigation?

Yes. The BioZorb lawsuit is developing into a significant product liability case, similar to previous lawsuits involving defective breast implants and surgical mesh. Plaintiffs allege that the BioZorb marker causes severe complications, including chronic pain, infection, and migration. The litigation has gained momentum, with cases consolidated in the U.S. District Court of Massachusetts.

Why is BioZorb facing a recall, and how does it impact my case?

The BioZorb recall was classified as a Class I recall, the FDA’s most serious designation, indicating a high risk of injury or death. Hologic, the manufacturer, failed to adequately warn patients and doctors about the risks. If you suffered from BioZorb complications, this recall strengthens your case, demonstrating that the company was aware of the dangers but did not act in a timely manner.

Can I file a BioZorb implant lawsuit if I needed a second surgery?

Absolutely. Many plaintiffs in the BioZorb implant lawsuit have had to undergo additional surgeries because the device failed to resorb, caused painful scarring, or migrated. If you required a second procedure to remove your BioZorb implant, you likely have a strong claim.

What are the biggest allegations against Hologic in the BioZorb lawsuit?

The Hologic lawsuit claims that the company:

• Failed to warn doctors and patients about BioZorb’s risks.
• Misled surgeons into believing the device would fully resorb in 6-12 months.
• Promoted off-label uses, such as tissue filling and cosmetic enhancement.
• Delayed reporting of adverse events to the FDA.

These failures are central to the BioZorb recall lawsuit and could have significant legal and financial consequences for Hologic.

Did Hologic hide BioZorb‘s dangers from the public?

Key Litigation Questions

A central point of contention in the BioZorb complications lawsuit is whether Hologic was aware of the risks—specifically, significantly delayed resorption and migration—but still aggressively promoted the device. The FDA even cited Hologic for failing to report serious injuries promptly. This could allow a jury to award punitive damages, potentially leading to a substantial verdict that could increase BioZorb settlement amounts.

Are BioZorb Claims Part of a Class Action Lawsuit?

Not exactly. While the cases are being overseen by a single judge, there isn’t a formal BioZorb class action lawsuit. Instead, the cases are being coordinated to streamline the legal process, while still allowing each plaintiff to pursue individual compensation based on their specific injuries.

What Settlement Amounts Can Plaintiffs Expect?

Although it’s still early in the litigation, experts estimate that BioZorb settlements could range from $150,000 to $500,000 per plaintiff, contingent on the severity of the injuries. If juries decide to award punitive damages—particularly given Hologic’s alleged failure to warn—some verdicts could potentially exceed $1 million. More information about expected settlement payouts is provided below.

Does the FDA’s Warning Help My Lawsuit?

Yes, the FDA recently issued a recall notice for BioZorb, confirming the device’s serious health risks. While this evidence might not be directly admissible at trial, it shifts the dynamics of the litigation and puts Hologic on the defensive.

Why Are Women Suing Over BioZorb Breast Markers?

The lawsuits allege that BioZorb, despite being marketed as a safe radiographic marker for breast cancer patients, caused more harm than good. Instead of aiding recovery, it allegedly led to:

• Chronic pain and inflammation
• Infections and abscesses
• Device migration
• Scarring and disfigurement

Women who relied on this device are now dealing with life-altering complications and are seeking to hold Hologic accountable. If you’ve experienced these issues, contact Nguyen Injury Lawyer at XXX-XXX-XXXX to discuss your legal options.

Did Hologic Push BioZorb for Cosmetic Benefits That Weren’t FDA-Approved?

Yes, this is a major issue in the BioZorb marker recall lawsuits. While the FDA cleared BioZorb as a radiographic marker, Hologic allegedly marketed it as a tissue filler to improve breast shape after surgery. Patients who believed these claims now face permanent scarring and painful masses.

Do I Qualify for a BioZorb Lawsuit?

You may be eligible for a BioZorb lawsuit if you had a BioZorb implant after a lumpectomy or breast biopsy and experienced complications like pain, migration, infection, or required revision surgery. Even if your device hasn’t been removed yet, you may still have a valid claim based on potential long-term damage. Contact Nguyen Injury Lawyer at XXX-XXX-XXXX or visit our contact page for a free consultation.

What Is the Next Key Date in the BioZorb Litigation?

The first BioZorb lawsuit trial is scheduled for September 8, 2025, in the U.S. District Court of Massachusetts. This initial trial will provide insights into the strength of the plaintiffs’ cases and could encourage Hologic to pursue a settlement. If you’re considering legal action, it’s important to act now, as delaying could limit your options. Call Nguyen Injury Lawyer at XXX-XXX-XXXX to learn more.

BioZorb Lawsuit Updates

December 29, 2024: Cases Moving Towards Trial

BioZorb titanium breast marker lawsuits are progressing rapidly. Judge Burroughs has initiated a bellwether process to prepare representative claims for early trial dates.

In July 2024, Judge Burroughs instructed both parties to select 10 BioZorb lawsuits for a Discovery Pool, with each side designating five cases. These cases have undergone depositions, medical record exchanges, and other discovery to identify four cases for the initial bellwether trials.

A proposed case management order has identified the following four cases for the trial pool:

• Case 1: The plaintiff underwent a lumpectomy in October 2020, during which a BioZorb marker was implanted. The plaintiff later experienced complications, including lymphedema, a persistent wound, recurring staph infections, and a broken piece of the marker protruding from the skin in 2022, requiring surgical removal.
• Case 2: The plaintiff received a BioZorb implant during a lumpectomy in June 2021. The implant failed to absorb into the body, requiring a subsequent mastectomy to remove the device.
• Case 3: The plaintiff received a BioZorb implant in May 2018. The device caused severe pain and discomfort as it protruded from the chest, leading to its removal in May 2022.
• Case 4: The plaintiff received a BioZorb marker in June 2020 and has since reported complications, including pain, scarring, fibrosis, and an inability to sleep comfortably. The implant has not yet been removed.

The parties have proposed a random selection process to determine the trial order by January 17, 2025. Trials are expected to last approximately three weeks each, with the first trial scheduled for September 8, 2025, and the second in January 2026.

December 19, 2024 – Recall Notice

The FDA updated the recall notice yesterday.

December 17, 2024: Five-Plaintiff Lawsuit Filed

Five breast cancer survivors from Washington, Illinois, Maryland, and New York have filed claims against Massachusetts-based Hologic, Inc., alleging injuries caused by the company’s BioZorb Marker. The plaintiffs, who underwent lumpectomies or partial mastectomies, report severe complications, including pain, infection, device migration, scarring, disfigurement, and emotional distress.

The lawsuit, filed in federal court in Massachusetts, asserts that Hologic failed to adequately warn patients and healthcare providers of the risks associated with BioZorb, including prolonged resorption times, migration, and increased radiation exposure. Additionally, the plaintiffs contend that the company promoted unapproved uses of the device, including improving cosmetic outcomes and aiding radiotherapy. The plaintiffs seek compensatory and punitive damages for the harm they have suffered. Contact Nguyen Injury Lawyer at XXX-XXX-XXXX to discuss your legal options.

December 12, 2024: BioZorb Class Action Lawsuit

Plaintiffs’ lawyers anticipate a Hologic BioZorb class action lawsuit or, more specifically, an MDL next year. While the terms “class action” and “MDL” are often used interchangeably, they are distinct legal mechanisms.

A class action consolidates claims into one lawsuit with a single trial, representing all class members as a unified group. In contrast, a multidistrict litigation (MDL) centralizes individual cases before one court for pretrial proceedings, such as discovery and motions, but each case retains its individuality and can proceed to separate trials. MDLs are often used in product liability cases like BioZorb because the claims share common questions of fact, but the damages and circumstances vary significantly for each plaintiff, requiring individual trials or settlements.

Currently, there is no MDL. However, the judge assigned to these cases in Boston is treating the 100+ cases that have been filed as if there was a consolidated action.

December 10, 2024: Bigger Picture

The BioZorb lawsuits highlight systemic issues in how medical devices like the BioZorb Marker are brought to market. Allegations that Hologic marketed the device for unapproved uses and failed to provide adequate warnings raise concerns about whether corners were cut in the rush to profit from a vulnerable patient population. The FDA’s subsequent recall and safety communications suggest these risks were foreseeable but not properly addressed.

December 9, 2024: Off-Market Uses in Focus

Plaintiffs’ Biozorb Marker lawsuits emphasize allegations of off-label promotion. While the FDA approved BioZorb for radiographic marking, the device was allegedly marketed to fill tissue gaps and improve cosmetic outcomes—claims the FDA explicitly did not approve. This discrepancy raises the question of whether patients were unknowingly subjected to unapproved uses of a device that introduced unforeseen risks. These suits will investigate how off-label marketing practices can blur the lines of responsibility, leaving patients to suffer the consequences of decisions they were not fully informed about.

December 7, 2024: FDA Calls for Reporting on Adverse Events

The FDA has reiterated the importance of patients and physicians reporting adverse events related to the BioZorb Marker through its MedWatch Online Voluntary Reporting System. This data collection aims to assess the full scope of complications associated with the device, emphasizing the regulatory body’s heightened concern over the product’s safety profile and the growing need for transparency in medical device monitoring. Experts believe this increased oversight could significantly influence new standards for post-market surveillance of medical devices.

December 1, 2024: Balancing Innovation with Safety

The BioZorb marker lawsuits reflect a broader challenge in healthcare: balancing innovation with patient safety. While advanced devices like BioZorb promise improved outcomes, they must undergo rigorous testing to ensure those benefits outweigh potential risks. When complications like migration and infection arise, it is often the patients—already in vulnerable states—who bear the burden. This lawsuit serves as a reminder that the pursuit of innovation should never come at the expense of transparency, safety, or the well-being of those the device is intended to help. The court’s handling of this case may set a benchmark for future litigation in the medical device field. If you’ve been affected, contact Nguyen Injury Lawyer at XXX-XXX-XXXX for guidance.

October 26, 2024: FDA Issues Safety Communication

The FDA released a Safety Communication advising healthcare providers and consumers to discontinue using BioZorb breast markers due to serious risks, including migration, pain, and infection. This announcement followed increasing reports of adverse events and underscored the regulatory agency’s recognition of the device’s failure to meet safety standards. The communication has prompted renewed discussions about how manufacturers disclose risks to providers and patients.

October 23, 2024: Hologic Announces Urgent Device Recall

Hologic, Inc. issued an urgent recall of all unused BioZorb Markers and BioZorb LP Markers, citing adverse outcomes, including rashes, fluid buildup, device migration, and the need for surgical removal. For patients and their healthcare providers, this recall marked a turning point, confirming the severity of the risks that had previously been suspected but not officially acknowledged. Analysts suggest that this recall will likely lead to significant financial and reputational challenges for Hologic.

September 28, 2024: Court Allows Plaintiffs’ Claims to Proceed

U.S. District Judge Allison D. Burroughs denied Hologic’s motion for summary judgment, enabling the claims to move forward. This decision was pivotal, affirming the plaintiffs’ right to pursue their allegations that the BioZorb Marker’s defective design caused significant harm and putting additional pressure on Hologic to either prepare for protracted litigation or consider settlement negotiations. Contact Nguyen Injury Lawyer at XXX-XXX-XXXX to discuss your legal options.

August 20, 2024 – “Sort of” BioZorb Class Action Lawsuit

For more information on the BioZorb lawsuit or to discuss your potential claim, please contact Nguyen Injury Lawyer at XXX-XXX-XXXX or visit https://www.nguyeninjurylawyer.com.

BioZorb Lawsuit Status

The BioZorb lawsuits are not proceeding as a multi-district litigation (MDL) class action. However, they are consolidated in the U.S. District Court for the District of Massachusetts and are being managed under a “bellwether” plan established by Judge Allison D. Burroughs. This plan involves selecting a small group of representative cases for early trials, which are scheduled to begin in July 2025. These trials will assess how juries respond to evidence suggesting that the BioZorb tissue marker had a defective design. The outcomes of these trials will provide insights into liability and potential BioZorb settlement compensation amounts.

June 5, 2024: Experts Question BioZorb Testing

Several industry experts have voiced concerns that the BioZorb Marker may not have undergone sufficient real-world testing before its release. These concerns were shared during a healthcare conference, where panelists emphasized the importance of simulating diverse patient scenarios during pre-market testing. This raises questions about the approval process for medical devices and whether regulatory agencies should mandate more rigorous real-life testing protocols.

May 15, 2024: 510(k) Approval Process

The BioZorb recall brings renewed attention to the FDA’s 510(k) approval process. Unlike the more stringent Premarket Approval (PMA) process, the 510(k) pathway does not require clinical trials if a device is deemed “substantially equivalent” to existing products. The question arises whether this approach is suitable for complex devices like BioZorb. Nguyen Injury Lawyer believes it is not.

Reliance on 510(k) approval is a central issue in many medical device lawsuits, where plaintiffs argue that this process allows manufacturers to avoid critical testing. In the BioZorb lawsuits, our attorneys are examining whether Hologic utilized this expedited pathway, bypassing necessary safeguards to prioritize speed to market over patient safety.

For plaintiffs, the FDA’s stance presents a double-edged sword: it supports claims of inadequate testing while also providing the defense with a potential argument that the device met regulatory standards at the time of approval. You can be sure Hologic will attempt to use the FDA’s initial approval as a defense in every BioZorb lawsuit that is filed.

May 1, 2024: FDA Classifies BioZorb Recall as Class I

The FDA officially classified the BioZorb recall as a Class I recall. This is the most serious category, reserved for situations where the use of a device could cause serious injury or death. This classification serves as a stark warning to both medical professionals and patients, further intensifying scrutiny of the device’s design and regulatory compliance.

February 26, 2024: Hologic Issues Medical Device Safety Notification

Hologic issued an initial safety notice to patients and healthcare providers, acknowledging potential risks associated with the BioZorb Marker, including device migration and infection. This early notice set the stage for further investigations into the device’s safety and signaled the beginning of what would become a large-scale recall and legal battle.

About the BioZorb Device

The BioZorb device, manufactured by Hologic, Inc., is an implantable marker designed to assist breast cancer patients following a lumpectomy. BioZorb is a three-dimensional, bioabsorbable structure composed of polylactic acid (PLA) with six titanium markers embedded in a spiral or circular design. These titanium clips act as radiopaque “targets,” enabling radiologists to accurately locate the site for focused radiation therapy.

While BioZorb was cleared by the FDA for marking breast tissue sites post-surgery, Hologic has marketed the device beyond these approved uses, promoting its benefits for filling tissue space and improving cosmetic outcomes—claims the FDA has not endorsed. This marketing has raised significant concerns, especially as BioZorb’s advertised benefits have led patients to expect better results in both radiation targeting and cosmetic recovery.

In fact, these off-label promotional claims are now central to the BioZorb lawsuit. Patients, like the plaintiff in the initial case, received this device believing it would resorb naturally and pose no long-term health risks. Unfortunately, this has not been the case for many women. Complaints of persistent pain, hardened masses, non-absorption, and the formation of scar tissue at the implantation site have become increasingly common. Worse yet, these complications can mimic the symptoms of new cancerous growths, leading to ongoing emotional trauma and distress.

FDA Public Safety Warning Regarding BioZorb

The FDA has issued two critical notices concerning BioZorb’s risks. In February 2024, the FDA released a public safety notice regarding the BioZorb. This notice warned patients and healthcare providers of the significant risk of serious health complications associated with the BioZorb.

The FDA noted that adverse event reports have indicated that the BioZorb can cause a number of complications, including infection, fluid buildup (seroma), device migration, device erosion, pain, discomfort from feeling the device in the breast, rash, and other complications possibly associated with extended resorption time.

The FDA classified Hologic’s notification to healthcare providers as a Class I recall, indicating a serious risk of injury or death. The safety notice warned that many of these complications can be harmful and require additional treatment, including surgery to remove the device.

The safety notice further explained that the BioZorb has only received FDA clearance for use as a radiographic marker for sites in soft tissue and has NOT been cleared or approved for use to fill space in tissue or improve cosmetic outcomes.

Overview of the BioZorb Lawsuit

Manufacturers of medical devices or implants, such as BioZorb, have a legal obligation to ensure that their products are safe for their intended use. When a product is unsafe due to a defective design, a manufacturing flaw, or a negligent failure to warn about certain risks, the manufacturer can be held responsible for injuries caused by that product.

The BioZorb lawsuit centers around an implantable device designed to serve as a three-dimensional marker for soft tissue sites after breast cancer surgeries like lumpectomies. While the device includes six titanium radiopaque clips intended to guide radiation therapy, plaintiffs in these cases allege that instead of seamlessly integrating into their recovery process, BioZorb has caused painful scarring and infection. These complications were allegedly not adequately disclosed, forming the basis of this litigation.

The BioZorb’s design, compounded by misleading marketing, has left many patients unprepared for the realities of their post-implantation experience. Biozorb lawsuits against Hologic assert that the company failed to adequately warn patients and doctors about the potential for serious complications, such as chronic pain, tissue inflammation, disfigurement, and device migration.

Plaintiffs argue that Hologic’s instructions for use (IFU) lack critical warnings about BioZorb’s slow or incomplete absorption and omit necessary information about increased radiation dosing risks, which can lead to visible skin damage. In marketing BioZorb as a space filler and cosmetic enhancer, Hologic is also accused of promoting off-label uses without disclosing the risks, potentially leading doctors to recommend the device without a full understanding of its safety profile.

Hologic, the manufacturer of BioZorb, may be required to provide settlement compensation to victims for injuries caused by complications associated with the implant. Individuals who had the BioZorb implanted and subsequently suffered complications caused by defects in its design or shortcomings in its instructions may be eligible to file a product liability claim and receive financial compensation. Contact Nguyen Injury Lawyer at XXX-XXX-XXXX for a free consultation.

A growing number of BioZorb lawsuits have already been filed across the country. Hundreds, and possibly thousands more, are expected as new patients suffer complications and injuries.

BioZorb Injuries and Complications

The BioZorb device, intended to aid in breast tissue marking and healing, has instead caused significant harm to many patients. One of the most critical issues involves the device failing to naturally resorb as promised, leading to additional invasive surgeries for removal. These surgeries often result in permanent disfigurement, scarring, and ongoing emotional distress.

Nguyen Injury Lawyer is actively investigating claims and accepting cases from individuals who have experienced the following injuries or complications linked to BioZorb implants:

• Infection: Severe and sometimes recurring infections at the implant site.
• Fluid Buildup (Seroma): Accumulation of fluid around the implant, causing discomfort and requiring medical intervention.
• Migration: Instances where the implant moves out of its intended position, leading to additional complications and corrective surgeries.
• Erosion: The implant breaks through the skin, resulting in pain and visible disfigurement.
• Delayed or Failed Reabsorption: The device not resorbing as intended, leaving a palpable lump, chronic pain, or requiring surgical removal.

BioZorb Marker Lawsuit & Titanium Breast Marker Lawsuit Timeline

2013-2015: Development & FDA Clearance

• 2013: BioZorb, a titanium-based breast marker, is developed by Focal Therapeutics, Inc., as a bioabsorbable device designed for breast cancer patients undergoing lumpectomy.
• 2014: The FDA grants 510(k) clearance for BioZorb, allowing its sale without requiring clinical trials, as it was deemed “substantially equivalent” to existing breast markers. Many lawsuits involve drugs and medical devices that received this 510(k) clearance.
• 2015: Focal Therapeutics begins marketing BioZorb, emphasizing its benefits for radiation targeting and claiming cosmetic improvements—despite no FDA approval for breast tissue reconstruction.

2016-2018: Adoption & Early Complaints

• 2016: BioZorb gains widespread use among breast surgeons, marketed as an innovative solution for marking lumpectomy sites.
• 2017: Reports emerge of severe complications, including device migration, chronic pain, infection, and non-absorption, leading to revision surgeries for removal.
• 2018: Patients file initial complaints alleging BioZorb is not bioabsorbing as expected, with some experiencing device protrusion years after surgery, fueling early BioZorb marker lawsuit discussions.

2019-2021: Hologic Acquisition & Increasing Concerns

• 2019: Hologic, Inc., acquires Focal Therapeutics for $125 million, inheriting BioZorb and its litigation risk.
• 2020: Lawsuits against BioZorb begin to surface as patients report ongoing pain, scarring, and device failures.
• 2021: Complaints increase as surgeons question whether the device’s rigid titanium clips contribute to prolonged complications, worsening patient outcomes.

2022-2023: Litigation Growth & FDA Scrutiny

• 2022: Patients suffering from severe complications seek legal representation, sparking a wave of BioZorb marker lawsuits over undisclosed risks.
• June 2023: The FDA initiates an investigation into BioZorb following a surge in adverse event reports from patients and surgeons.
• December 2023: Hologic faces increasing legal scrutiny as more women report unnecessary procedures and emotional distress due to BioZorb-related complications.

2024: FDA Recall & Explosive Lawsuits

• February 26, 2024: Hologic issues a safety warning admitting to potential risks, including device migration, infection, and pain.
• May 1, 2024: The FDA issues a Class I recall, citing a risk of serious injury or death from BioZorb complications.
• June 5, 2024: The concerns over BioZorb testing were raised.

BioZorb Litigation Timeline

Medical experts have publicly questioned the FDA’s approval process, asserting that BioZorb should have been subjected to clinical trials before being cleared for market use, rather than circumventing standard procedures.

August 20, 2024: BioZorb breast marker lawsuits are consolidated under Judge Allison Burroughs in the U.S. District Court of Massachusetts. Note that this is not a class action lawsuit or MDL.

September 28, 2024: Judge Burroughs denies Hologic’s motion to dismiss, allowing BioZorb marker lawsuits to proceed.

October 23, 2024: Hologic initiates a nationwide recall of all remaining BioZorb units due to significant safety concerns.

December 12, 2024: Over 100 lawsuits have been filed against Hologic. Nguyen Injury Lawyer anticipates more filings, but does not expect this to become a large mass tort.

2025: Litigation Moves Toward Trial

January 16, 2025: Judge Burroughs denies Hologic’s motion for summary judgment, clearing the way for the first BioZorb marker lawsuit bellwether trial.

January 29, 2025: The FDA issues a warning letter to Hologic, citing design flaws, inadequate safety testing, and failure to report adverse events.

February 13, 2025: Plaintiffs attempt to introduce recall evidence in early cases, but the court denies the motion. While this type of evidence is generally inadmissible at trial, plaintiffs believed they had grounds for exceptions.

February 21, 2025: Judge Burroughs schedules the first BioZorb trial for September 8, 2025, with these bellwether cases expected to influence settlement negotiations.

BioZorb Legal Allegations and Theories of Liability

In the BioZorb lawsuits, plaintiffs are pursuing claims based on legal theories including failure to warn, design defect, and negligence. The core argument is that Hologic was aware—or should have been aware—of the potential risks linked to the BioZorb device, yet failed to provide adequate warnings to physicians and patients.

Failure to Warn

The instructions for use (IFU) accompanying the BioZorb device lack crucial information regarding the potential for non-absorption, hardened masses, and long-term complications. While the IFU suggests the device may resorb within one year, plaintiffs report cases where the device failed to resorb, leading to painful and disfiguring outcomes. Furthermore, marketing materials included claims about improved cosmetic results and post-surgical recovery benefits that lacked clinical data and exceeded the FDA’s clearance scope.

Design Defect

The design of the BioZorb device, with its spiral or helical shape and bioabsorbable polylactic acid compound, may be inherently flawed. These design elements contribute to complications such as infection, migration, and increased radiation exposure, potentially requiring additional surgeries. Plaintiffs argue this risk-benefit imbalance should have been addressed by the manufacturer.

General Negligence

Hologic’s failure to adequately test and monitor BioZorb’s performance, along with promoting the device for off-label uses, has harmed patients. Plaintiffs contend that adhering to reasonable standards of care could have prevented or mitigated many complications.

Contact Us About a BioZorb Lawsuit

If you have experienced complications related to a BioZorb implant device, please contact Nguyen Injury Lawyer today for a free consultation. Call us at XXX-XXX-XXXX or reach out through our online contact form.